Skip to content
Federal Budget, Medical Health Aged Care

ANZGOG welcomes the Federal Budget’s investment in medical research and clinical trials and highlights the need for continued focus on gynaecological cancers

Australia New Zealand Gynaecological Oncology Group (ANZGOG) 2 mins read

MEDIA RELEASE 
FOR IMMEDIATE RELEASE 

 

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) welcomes key initiatives in the Federal Budget that will support Australians living with gynaecological cancer. This includes investment in medical research, clinical trials, Pharmaceutical Benefits Scheme (PBS), Medicare and support for our healthcare workers. 

 

ANZGOG acknowledges the Federal Government’s commitment of $158.6 million over five years to support medical research and the translation of research into clinical practice, alongside the $150.3 million investment in expanding precision oncology programs, including the Australian Rare Cancers Portal. These investments represent a positive step in strengthening Australia’s healthcare system and advancing cancer care. 

 

However, with 19 women diagnosed with a gynaecological cancer every day, and more than half facing a rare or less common cancer with limited treatment options and poor survival rates, ANZGOG recognises the critical need for increased investment and collaboration in this area to change treatment, catalyse research and save women’s lives. 

 

ANZGOG Chair, Professor Clare Scott AM, said the organisation is committed to working with government and the broader health sector to ensure women with gynaecological cancers receive the same level of research investment and treatment innovation as those diagnosed with other cancers. 

 

"With the number of Australian women impacted by gynaecological cancer rising, it is essential that we continue to strengthen research and clinical trial investment to drive better outcomes. ANZGOG stands ready to collaborate with government, the health sector, and research partners to support, connect and implement these important initiatives." 

 

ANZGOG looks forward to working with the Federal Government to build on these Budget measures, as well as partnering with the Medical Research Future Fund, the Australian Cancer Plan, and the National Framework for Genomics in Cancer Control.   

 

Through targeted investment and transformative research, we can improve the diagnosis, treatment, and care of gynaecological cancers—delivering better outcomes for all those affected. - ENDS - 


About us:

About ANZGOG: The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation in Australia and New Zealand. Our vision is: Advancing research, Saving Lives. The group has more than 1500 members representing clinical, allied health and pure research specialties, and includes community. ANZGOG clinical trials are conducted at over 80 hospital sites and include both local and global collaborations to ensure the best research is available to improve life for women with a gynaecological cancer. 


Contact details:

Media inquiries: Monique Cerreto T: 0416 282 464 E: [email protected]  

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/12/2025
  • 09:02
UNSW Sydney

UNSW students claim victory in international artificial heart competition

A team of undergraduate engineering students from UNSW Sydney has claimed first place at a prestigious international artificial heart design competition in Vienna. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.